Cantor Fitzgerald says it's lowering its rating on Obagi Medical Products (OMPI +0.2%) from Buy...

|About: Obagi Medical Products, Inc. (OMPI)|By:, SA News Editor

Cantor Fitzgerald says it's lowering its rating on Obagi Medical Products (OMPI +0.2%) from Buy to Hold on the back of yesterday's merger announcement with Valeant Pharmaceuticals (VRX +0.2%). Cantor says the deal is generally in line with other historical deals in the dermatology space, and after speaking with management it believes the deal has been fully shopped and there aren't likely to be any competing bids.